Cetuximab with radiotherapy does not increase side effects for head and neck cancer patientsJanuary 19, 2007The addition of Cetuximab (brand name Erbitux) to radiation therapy treatments does not increase the rate or duration of some side effects in the treatment of advanced head and neck cancers, according to a study presented at the plenary session today at the Multidisciplinary Head and Neck Cancer Symposium, co-sponsored by the American Society for Therapeutic Radiology and Oncology, the American Society for Clinical Oncology and the American Head and Neck Society. This study was an in-depth look at outcomes from a study published in the New England Journal of Medicine in 2006 that showed that patients with locally advanced head and neck cancer who were given Cetuximab in addition to radiation therapy, showed not only a survival benefit, but also that there was no increase in mucositis (reddening, swelling and pain of the mucous membrane) or dysphagia (difficulty or pain when swallowing) over patients who received radiation therapy alone. This study compared the duration of these normal tissue toxicities between the two arms from the NEJM study. There were 424 patients involved in this study and the median follow-up time was 54 months. For the overall group, the median duration of any mucositis or dysphagia was three months. Of the patients with mucositis, 28 percent experienced this toxicity for three months. Of those with dysphagia, 31.5 percent experienced this toxicity for three months. Fewer than 10 percent suffered from these toxicities for more than 15 weeks. These findings were similar for the two treatment arms. "These findings are important because they show that the addition of this monoclonal antibody therapy has lifesaving benefits without any additional length of suffering from the primary acute side effects," said James A. Bonner, M.D., lead author of the study and a radiation oncologist at the University of Alabama in Birmingham, Ala. American Society for Therapeutic Radiology and Oncology |
|||||||||||||||||||||
| Related Radiotherapy Current Events and Radiotherapy News Articles Study of concurrent radiotherapy, chemotherapy shows promise in small cell lung cancer Treating limited stage small cell lung cancer(LSCL) with a combination of accelerated high-dose radiotherapy and chemotherapy has shown encouraging results. Blood vessels might predict prostate cancer behavior A diagnosis of prostate cancer raises the question for patients and their physicians as to how the tumor will behave. Will it grow quickly and aggressively and require continuous treatment, or slowly, allowing therapy and its risks to be safely delayed? Stereotactic radiotherapy offers noninvasive, effective treatment for frail patients with early-stage lung cancer Stereotactic body radiation therapy (SBRT) should be considered a new standard of care for early-stage lung cancer treatment in patients with co-existing medical problems, according to results from a national clinical trial led by UT Southwestern Medical Center physicians. Short-term hormone therapy and intermediate dose radiation increases survivial for early stage prostate cancer Short-term hormone therapy given prior to and during intermediate dose radiation treatment for men with early stage prostate cancer increases their chance of living longer, compared to those who receive the same radiation alone. Herbal tonic for radiotherapy Antioxidant extracts of the leaves of the Gingko biloba tree may protect cells from radiation damage, according to a study published in the International Journal of Low Radiation. Exercise reduces fatigue in cancer patients undergoing chemotherapy Supervised exercise programmes that include high and low intense cardiovascular and resistance training can help reduce fatigue in patients with cancer who are undergoing adjuvant chemotherapy or treatment for advanced disease. Although more older women receive breast-conserving therapy, gaps in treatment exist According to a new study published in the October issue of the Journal of the American College of Surgeons, although breast-conserving surgery (BCS), commonly known as lumpectomy, is increasingly being used to treat older women with nonmetastatic invasive breast cancer, there are still significant socioeconomic and geographic disparities in the use of this type of therapy. Prediction model superior to traditional criteria in bladder treatment decision A statistical model can accurately predict which patients will have poor outcomes after bladder surgery and can determine the need for chemotherapy. New Approach for the Treatment of Malignant Brain Tumors Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. Mayo Clinic Researchers Find Few Side Effects from Radiation Treatment Given After Prostate Cancer Surgery The largest single-institution study of its kind has found few complications in prostate cancer patients treated with radiotherapy after surgery to remove the prostate. More Radiotherapy Current Events and Radiotherapy News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||